This article is more than 5 years old. Information may no longer be current.

FDA declines stent thrombosis indication for rivaroxaban

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has issued a complete response letter to Jannsen Pharmaceuticals today that declines the request of the manufacturer to expand the indication of its factor Xa inhibitor rivaroxaban to include the reduction of stent thrombosis in patients with ACS.

This news comes after the FDA’s decision in March to reject for a second time the company’s supplemental new drug application (NDA) for an ACS indication for rivaroxaban (Xarelto).

Christopher Nessel, MD, vice president and cardiovascular franchise medical leader at Janssen, said in a press release that the company remains confident in the results of the ATLAS ACS 2-TIMI 51 trial and are in ongoing discussions with the FDA regarding this supplemental NDA.

Rivaroxaban is currently the only factor Xa inhibitor FDA approved for six indications, including reducing the risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment of deep vein thrombosis or pulmonary embolism and reduction of risk for recurrence after initial treatment.